SNDX - Syndax Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5270.35M
Enterprise Value 3234.37M
Trailing P/E N/A
Forward P/E 1-4.86
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)178.22
Price/Book (mrq)7.68
Enterprise Value/Revenue 3154.50
Enterprise Value/EBITDA 6-4.08

Trading Information

Stock Price History

Beta (5Y Monthly) 2.06
52-Week Change 354.94%
S&P500 52-Week Change 3-14.06%
52 Week High 312.27
52 Week Low 35.35
50-Day Moving Average 39.99
200-Day Moving Average 38.38

Share Statistics

Avg Vol (3 month) 3253.84k
Avg Vol (10 day) 3192.91k
Shares Outstanding 530.18M
Float 20.81M
% Held by Insiders 19.55%
% Held by Institutions 164.15%
Shares Short (Mar. 12, 2020) 41.21M
Short Ratio (Mar. 12, 2020) 44.47
Short % of Float (Mar. 12, 2020) 45.12%
Short % of Shares Outstanding (Mar. 12, 2020) 43.99%
Shares Short (prior month Feb. 13, 2020) 4842.1k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Dec. 30, 2019


Profit Margin 0.00%
Operating Margin (ttm)-3,792.95%

Management Effectiveness

Return on Assets (ttm)-48.77%
Return on Equity (ttm)-132.42%

Income Statement

Revenue (ttm)1.52M
Revenue Per Share (ttm)0.05
Quarterly Revenue Growth (yoy)0.00%
Gross Profit (ttm)1.52M
EBITDA -57.45M
Net Income Avi to Common (ttm)-56.05M
Diluted EPS (ttm)-1.84
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)61.07M
Total Cash Per Share (mrq)2.02
Total Debt (mrq)897k
Total Debt/Equity (mrq)2.84
Current Ratio (mrq)3.39
Book Value Per Share (mrq)1.16

Cash Flow Statement

Operating Cash Flow (ttm)-50.61M
Levered Free Cash Flow (ttm)-27.57M